Erudio Bio

Erudio powers AI drug discovery with ground-truth binding data.
Our Versatile Smart Assay (VSA) converts molecular interactions into kinetics-resolved “stickiness” labels (force curves, on/off characteristics) at scale. These labels train and validate AI models so they rank true binders and filter look-alikes early.

With bioTCAD, our data + software layer, teams cut wet-lab cycles and de-risk candidates before expensive assays.

(Multiplex is how we scale: VSA reads 50–100 interactions from ~10 µL in a single run.)

News

Erudio Bio Receives Grant to Advance bioTCAD™ for global health

August 30, 2025 — Erudio Bio today announced a grant from the Gates Foundation to support bioTCAD™, an AI platform that pairs advanced modeling with Erudio’s multiplex force-spectroscopy binding measurements. The project aims to make preclinical drug design more reliable and faster—ultimately lowering the cost of developing medicines for diseases that disproportionately affect people in low- and middle-income countries.

“AI needs trustworthy experimental labels to predict what actually works,” said Kee-Hyun Paik, PhD, Erudio’s co-founder and CEO. “With the foundation’s funding support, we’ll scale bioTCAD to generate high-quality binding data and put it to work on high-burden diseases.”

About Erudio Bio
Erudio Bio is building the measurement and software stack for binding-aware AI in drug discovery. Its benchtop reader and chip convert force-of-binding curves into machine-ready features that help researchers prioritize candidates earlier and more accurately. Learn more at erudio.bio.

Link to Gates Foundation Erudio Bio Grant

Alexa Young, CA

Our Services

Our Technology

Our innovative patented technology addresses critical limitations in current multiplexed assay methods, and provides comprehensive binding data that opens new possibilities in disease detection and drug development.

Powering AI drug discovery

Erudio provides the missing ingredient for AI-powered drug discovery: ground-truth binding labels that capture both strength and kinetics. Our datasets let models separate true binders from look-alikes and activity cliffs, improving hit ranking, calibration, and go/no-go decisions across the pipeline.

Comprehensive Data with Force Spectroscopy

Our patented dynamic force spectroscopy reads the energy needed to pull molecules apart, revealing on/off rates, unbinding forces, and specificity. By measuring kinetics—not just presence—we filter out cross-reactivity and non-specific binding, enabling accurate, comprehensive multiplexed assays in complex samples.

Scalable Data Generation

VSA reads 50–100 interactions per run from just ~10 µL samples, enabling rapid build-out of task-specific panels across cytokines, antibodies, and glycans. That scale turns individual force curves into production-grade datasets—fuel for both early discovery and downstream validation.

Our Team

Meet the Team

Meet the brilliant minds driving innovation at Erudio Bio, Inc. Our diverse team of scientists, researchers, and visionaries is dedicated to revolutionizing the biotech industry.